75.15

1.46% 1.085

Bridgebio Pharma Inc (BBIO)

Overview News Price History Option Chain Financials Why BBIO Down? Discussions Forecast

Bridgebio Pharma Inc stock is traded at $75.15, with a volume of 1.60M. It is up +1.46% in the last 24 hours and up +13.49% over the past month. BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Previous Close:

$74.06

Open:

$73.83

24h Volume:

1.60M

Relative Volume:

0.70

Market Cap:

$14.48B

Revenue:

$217.77M

Net Income/Loss:

$-438.86M

P/E Ratio:

-31.18

EPS:

-2.41

Net Cash Flow:

$-456.33M

1W Performance:

+2.05%

1M Performance:

+13.49%

6M Performance:

+89.53%

1Y Performance:

+171.59%

1-Day Range:

$72.65

$75.24

1-Week Range:

$70.35

$75.24

52-Week Range:

$25.34

$75.24

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name

Bridgebio Pharma Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(650) 391-9740

Address

3160 PORTER DR., PALO ALTO, CA

Employee

730

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

BBIO's Discussions on Twitter

Compare BBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BBIO Bridgebio Pharma Inc	75.15	14.27B	217.77M	-438.86M	-456.33M	-2.41
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Jul-14-25	Initiated	Jefferies	Buy
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Mar-31-25	Initiated	Redburn Atlantic	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight
Mar-21-24	Resumed	Raymond James	Outperform
Jan-31-24	Initiated	BMO Capital Markets	Market Perform
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Jul-18-23	Downgrade	Jefferies	Buy → Hold
Apr-19-23	Initiated	Evercore ISI	Outperform
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	Mizuho	Buy
Dec-27-21	Reiterated	SVB Leerink	Outperform
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy
May-21-21	Initiated	UBS	Buy
Mar-22-21	Reiterated	Goldman	Buy
Feb-22-21	Resumed	JP Morgan	Overweight
Feb-09-21	Resumed	Goldman	Buy
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Dec-10-20	Reiterated	H.C. Wainwright	Buy
Jun-25-20	Initiated	BofA/Merrill	Neutral
May-19-20	Initiated	BTIG Research	Buy
Apr-13-20	Initiated	H.C. Wainwright	Buy
Feb-19-20	Initiated	Mizuho	Buy
Jul-26-19	Initiated	Raymond James	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform
Jul-22-19	Initiated	Goldman	Buy
Jul-22-19	Initiated	JP Morgan	Overweight
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Piper Jaffray	Overweight
Jul-22-19	Initiated	SVB Leerink	Outperform

View All

Bridgebio Pharma Inc Stock (BBIO) Latest News

Dec 12, 2025

BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha

Dec 12, 2025

BridgeBio Pharma stock hits all-time high at 75.13 USD By Investing.com - Investing.com Australia

Dec 12, 2025

BridgeBio Pharma (BBIO) Valuation After Attruby-Driven Earnings Beat and Renewed Analyst Support - Yahoo Finance

Dec 12, 2025

What Recent Clinical Wins Mean For BridgeBio Pharma’s Evolving Growth Story - Yahoo Finance

Dec 12, 2025

Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Dec 12, 2025

Dec 11, 2025

Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target - marketscreener.com

Dec 11, 2025

This Option Care Health Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga

Dec 11, 2025

HighVista Strategies LLC Increases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Dec 11, 2025

Bernstein Initiates Coverage of BridgeBio Pharma (BBIO) with Outperform Recommendation - Nasdaq

Dec 11, 2025

BBIO Gets "Outperform" Rating as Bernstein Initiates Coverage | - GuruFocus

Dec 11, 2025

Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating By Investing.com - Investing.com UK

Dec 11, 2025

Dec 10, 2025

BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer T - GuruFocus

Dec 10, 2025

BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer Treatment - GuruFocus

Dec 10, 2025

Apuli Maricel, chief accounting officer, sells $148k in BridgeBio (BBIO) - Investing.com Canada

Dec 10, 2025

This Hot Biotech Stock Just Set New All-Time Highs - Barchart.com

Dec 10, 2025

Insider Sell Alert: Maricel Apuli Sells 2,000 Shares of BridgeBi - GuruFocus

Dec 10, 2025

Dec 09, 2025

89,312 Shares in BridgeBio Pharma, Inc. $BBIO Acquired by WINTON GROUP Ltd - MarketBeat

Dec 09, 2025

Dec 08, 2025

Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat

Dec 08, 2025

BridgeBio Pharma CEO Kumar sells $5.9 million in BBIO stock By Investing.com - Investing.com Canada

Dec 08, 2025

Bridgebio Pharma Insider Sold Shares Worth $5,908,476, According to a Recent SEC Filing - marketscreener.com

Dec 08, 2025

BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighTime to Buy? - MarketBeat

Dec 08, 2025

Dec 07, 2025

Price-Driven Insight from (BBIO) for Rule-Based Strategy - news.stocktradersdaily.com

Dec 07, 2025